{"organizations": [], "uuid": "fb61b0d3eb0be7d33015153bd03f817da526a270", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-updates-on-sec/brief-mabvax-therapeutics-updates-on-sec-investigation-accounting-discrepancies-idUSFWN1SS0JF", "country": "US", "domain_rank": 408, "title": "BRIEF-Mabvax Therapeutics Updates On SEC Investigation, Accounting Discrepancies", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-21T22:58:00.000+03:00", "replies_count": 0, "uuid": "fb61b0d3eb0be7d33015153bd03f817da526a270"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-updates-on-sec/brief-mabvax-therapeutics-updates-on-sec-investigation-accounting-discrepancies-idUSFWN1SS0JF", "ord_in_thread": 0, "title": "BRIEF-Mabvax Therapeutics Updates On SEC Investigation, Accounting Discrepancies", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "mabvax therapeutics holdings inc", "sentiment": "negative"}, {"name": "sec investigation", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - MabVax Therapeutics Holdings Inc :\n* MABVAX THERAPEUTICS SAYS IN LIGHT OF SEC INVESTIGATION, UNABLE TO FILE FORM 10-Q FOR QUARTER ENDED MARCH 31, 2018 AT THIS TIME - SEC FILING\n* MABVAX THERAPEUTICS- BELIEVE SEC INVESTIGATING POTENTIAL VIOLATIONS BY CO, OFFICERS & POTENTIAL VIOLATIONS BY MULTIPLE HOLDERS OF PREFERRED STOCK\n* MABVAX THERAPEUTICS HOLDINGS INC - FURTHER BELIEVE SEC INVESTIGATION PERTAINS TO RELATIONSHIPS WITH MULTIPLE HOLDERS OF PREFERRED STOCK\n* MABVAX THERAPEUTICS - APPOINTED SPECIAL COMMITTEE WITH INDEPENDENT MEMBERS OF BOARD TO SUPERVISE REVIEW OF MATTERS BELIEVED TO BE UNDER INVESTIGATION\n* MABVAX THERAPEUTICS HOLDINGS INC - REVIEWING OUR INTERNAL AND DISCLOSURE CONTROLS\n* MABVAX THERAPEUTICS HOLDINGS - ON MAY 20, AUDITORS WITHDREW THEIR AUDIT REPORTS INCLUDED IN ANNUAL REPORTS ON FORM 10-K FOR YRS 2014, 2015, 2016, 2017\n* MABVAX - FINANCIAL STATEMENTS FOR 2014, 2015, 2016, 2017, REGISTRATION STATEMENTS FILED DURING THOSE YRS, TO DATE FOR 2018, SHOULD NOT BE RELIED UPON Source text : ( bit.ly/2rZ7Gqg ) Further company coverage:\n ", "external_links": ["http://bit.ly/2rZ7Gqg", "https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://www.youtube.com/user/ReutersVideo", "https://instagram.com/reuters/"], "published": "2018-05-21T22:58:00.000+03:00", "crawled": "2018-05-22T19:37:37.090+03:00", "highlightTitle": ""}